Spurred by Horizon 2020’s European Union funding for Research and Innovation funding, MoTriColor (Molecularly guided Trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of Colorectal cancer), led by VHIO, is powered by a total of eight clinical research centers of excellence spanning Spain, Italy, The Netherlands and Belgium, as well as the European Organisation for Research and Treatment of Cancer (EORTC), and a diagnostic/prognostic SME.
Dedicated to conducting multi-center early phase clinical trials to establish the anti-tumor activity of novel experimental therapies for patients with metastatic or advanced colorectal cancer, patients are stratified based on their gene expression profiles according to recently established predictive signatures, and response and resistance to selected therapies tracked by liquid biopsy.
VHIO’s role in MoTriColor
Coordinated by VHIO’s Director, Josep Tabernero, who leads this pioneering undertaking as Principal Investigator, our appointed team of researchers and clinical investigators are involved in the development of all the Work Packages, with a key role in the clinical research activities, leading WP4, clinical trial 3, and implicated in WPs 2 and 3 (clinical trial 1 and 2, respectively). As project lead, we are also responsible for driving WPs 8 and 9: Scientific Coordination and Project Management as well as Dissemination and Exploitation.
We invite you to download the Consortium’s official video that has just launched here:
This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. GA635342.